Literature DB >> 31888245

Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums.

Vladimir V Bamm1, Jordan T Ko1, Iain L Mainprize1, Victoria P Sanderson1, Melanie K B Wills1.   

Abstract

Lyme disease is a complex tick-borne zoonosis that poses an escalating public health threat in several parts of the world, despite sophisticated healthcare infrastructure and decades of effort to address the problem. Concepts like the true burden of the illness, from incidence rates to longstanding consequences of infection, and optimal case management, also remain shrouded in controversy. At the heart of this multidisciplinary issue are the causative spirochetal pathogens belonging to the Borrelia Lyme complex. Their unusual physiology and versatile lifestyle have challenged microbiologists, and may also hold the key to unlocking mysteries of the disease. The goal of this review is therefore to integrate established and emerging concepts of Borrelia biology and pathogenesis, and position them in the broader context of biomedical research and clinical practice. We begin by considering the conventions around diagnosing and characterizing Lyme disease that have served as a conceptual framework for the discipline. We then explore virulence from the perspective of both host (genetic and environmental predispositions) and pathogen (serotypes, dissemination, and immune modulation), as well as considering antimicrobial strategies (lab methodology, resistance, persistence, and clinical application), and borrelial adaptations of hypothesized medical significance (phenotypic plasticity or pleomorphy).

Entities:  

Keywords:  Borrelia; Lyme disease; antimicrobials; chronic Lyme disease; pathogenesis; pleomorphy; post-treatment Lyme disease syndrome; predisposition; serotype; virulence

Year:  2019        PMID: 31888245      PMCID: PMC6963551          DOI: 10.3390/pathogens8040299

Source DB:  PubMed          Journal:  Pathogens        ISSN: 2076-0817


  346 in total

1.  Two-year evaluation of Borrelia burgdorferi culture and supplemental tests for definitive diagnosis of Lyme disease.

Authors:  Peggy Coulter; Clara Lema; Diane Flayhart; Amy S Linhardt; John N Aucott; Paul G Auwaerter; J Stephen Dumler
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 2.  A critical appraisal of "chronic Lyme disease".

Authors:  Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

3.  An update on the diagnosis and treatment of early Lyme disease: "focusing on the bull's eye, you may miss the mark".

Authors:  Amber Stonehouse; James S Studdiford; C Amber Henry
Journal:  J Emerg Med       Date:  2007-10-18       Impact factor: 1.484

4.  Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure.

Authors:  Jie Feng; Tingting Li; Rebecca Yee; Yuting Yuan; Chunxiang Bai; Menghua Cai; Wanliang Shi; Monica Embers; Cory Brayton; Harumi Saeki; Kathleen Gabrielson; Ying Zhang
Journal:  Discov Med       Date:  2019-03       Impact factor: 2.970

Review 5.  Mechanism of complement resistance of pathogenic Borrelia burgdorferi isolates.

Authors:  P Kraiczy; C Skerka; M Kirschfink; P F Zipfel; V Brade
Journal:  Int Immunopharmacol       Date:  2001-03       Impact factor: 4.932

6.  gyrB mutations in coumermycin A1-resistant Borrelia burgdorferi.

Authors:  D S Samuels; R T Marconi; W M Huang; C F Garon
Journal:  J Bacteriol       Date:  1994-05       Impact factor: 3.490

7.  The role of bacterial biofilms in chronic infections.

Authors:  Thomas Bjarnsholt
Journal:  APMIS Suppl       Date:  2013-05

8.  A newly discovered cholesteryl galactoside from Borrelia burgdorferi.

Authors:  Gil Ben-Menachem; Joanna Kubler-Kielb; Bruce Coxon; Alfred Yergey; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

9.  Viable Borrelia burgdorferi enhances interleukin-10 production and suppresses activation of murine macrophages.

Authors:  John J Lazarus; Maria A Kay; Akisha L McCarter; R Mark Wooten
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

10.  Biomechanics of Borrelia burgdorferi Vascular Interactions.

Authors:  Rhodaba Ebady; Alexandra F Niddam; Anna E Boczula; Yae Ram Kim; Nupur Gupta; Tian Tian Tang; Tanya Odisho; Hui Zhi; Craig A Simmons; Jon T Skare; Tara J Moriarty
Journal:  Cell Rep       Date:  2016-08-25       Impact factor: 9.423

View more
  3 in total

Review 1.  Borreliella burgdorferi Antimicrobial-Tolerant Persistence in Lyme Disease and Posttreatment Lyme Disease Syndromes.

Authors:  Felipe C Cabello; Monica E Embers; Stuart A Newman; Henry P Godfrey
Journal:  mBio       Date:  2022-04-25       Impact factor: 7.786

2.  Pathogenesis of Fungal and Bacterial Microbes.

Authors:  Jennifer Geddes-McAlister
Journal:  Pathogens       Date:  2020-07-23

3.  Emergence of Lyme Disease on the French Riviera, a Retrospective Survey.

Authors:  Jacques Sevestre; Antoine Benichou; Vanessa Rio; Pascal Delaunay; Géraldine Gonfrier; Cécile Martaresche; Virginie Carlo; Sarah Nakam; Véronique Mondain; Michel Carles; Pierre Yves Jeandel; Jacques Durant
Journal:  Front Med (Lausanne)       Date:  2022-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.